Novavax (NVAX) Inventory (2021 - 2026)

Novavax's Inventory history runs 6 years deep, the most recent figure standing at $11.5 million for Q1 2026.

• In Q1 2026, Inventory rose 11.64% year-over-year to $11.5 million; the TTM figure through Mar 2026 stood at $11.5 million (up 11.64% YoY), while the FY2025 annual figure was $11.5 million, up 31.96% from the prior year.
• Inventory was $11.5 million for Q1 2026 at Novavax, down from $11.5 million in the prior quarter.
• In the past five years, Inventory ranged from a high of $256.3 million in Q2 2022 to a low of $8.6 million in Q3 2024.
• Historically, Inventory has averaged $44.1 million across 5 years, with a median of $15.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Inventory surged 313.47% in 2022, then plunged 90.84% in 2023.
• A 5-year view of Inventory shows it stood at $36.7 million in 2022, then increased by 13.67% to $41.7 million in 2023, then sank by 79.02% to $8.7 million in 2024, then jumped by 31.96% to $11.5 million in 2025, then retreated by 0.75% to $11.5 million in 2026.
• The last three Inventory figures came in at $11.5 million (Q1 2026), $11.5 million (Q4 2025), and $13.5 million (Q3 2025), per Business Quant data.